Natural Vascular Scaffold (NVS) Therapy for Treatment of Atherosclerotic Lesions (Activate I)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04188262|
Recruitment Status : Completed
First Posted : December 5, 2019
Last Update Posted : July 14, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Peripheral Arterial Disease Peripheral Vascular Diseases Catheterization, Peripheral||Combination Product: NVS Therapy||Phase 1|
This is a prospective, non-randomized, multi-center, open label Phase 1 study to assess the safety, pharmacokinetics (PK), and preliminary efficacy trends to applying NVS therapy to de novo lesions in the superficial femoral artery (SFA) and the proximal popliteal artery (PPA) during percutaneous transluminal angioplasty (PTA) in patients with life-style limiting claudication due to obstructive SFA and proximal popliteal artery atherosclerosis. Each investigator will receive supervised training for each procedure.
Eligibility to participate in the study is determined during the screening period and prior to the index procedure with the NVS therapy. Study Data will be analyzed through the Day 365 follow-up visit.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease|
|Masking:||None (Open Label)|
|Official Title:||Natural Vascular Scaffolding (NVS) Therapy for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)|
|Actual Study Start Date :||May 22, 2020|
|Actual Primary Completion Date :||April 5, 2022|
|Actual Study Completion Date :||May 31, 2022|
Experimental: NVS Therapy
NVS Therapy will be delivered to de novo lesions in Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
Combination Product: NVS Therapy
Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS light Fiber, and NVS light source.
Other Name: Natural Vascular Scaffold
- Freedom from all-cause mortality, freedom from target limb major amputation, freedom from target lesion revascularization (TLR). [ Time Frame: Day 30 ]The overall composite occurrence of participants free from all-cause mortality, target limb major amputation, target lesion revascularization (TLR) through post-index procedure Day 30 will be summarized as a percentage.
- NVS Drug Plasma Concentrations [ Time Frame: Day 1 - 24 (Or Discharge) ]The Peak Plasma Concentration (Cmax) will be determined from plasma 10-8-10 Dimer concentrations for blood samples collected.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
General Description of Subject Population: Adults with symptoms of claudication and/or rest pain (Rutherford Classification 2, 3, or 4) (see Appendix 3) and angiographic evidence of an atherosclerotic lesion of the superficial femoral artery and/or proximal popliteal artery ≥70% diameter stenosis and < 100% stenosis.
Subjects must meet all of the following general eligibility criteria:
- Subject is at least 18 years of age.
- Subject (or legally authorized representative [LAR]) understands the study requirements and the treatment procedure and provides written informed consent before any study-specific tests or procedures are performed.
- Subject is eligible for PTA.
- Subject is willing to comply with all protocol required follow-up evaluations.
- Subject has documented Rutherford Classification 2 to 4 (see Appendix 3).
- Subject has laboratory test results that are within clinically acceptable limits.
- In investigator's opinion, subject is hemodynamically stable at the time of the index procedure.
- Subject has a life expectancy of ≥ 1 year in the opinion of the Investigator.
- Subject is able to tolerate the insertion of a 7F sheath into the common femoral artery (CFA), as determined by the investigator.
- Subject is able to undergo contralateral access, as determined by the Investigator.
Subjects must not meet any of the following general eligibility criteria:
- Subject had cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 3 months prior to enrollment with any residual deficit involving the index lower extremity.
- Subject has any permanent neurologic defect that may impair ambulation and/or cause non-compliance with the protocol.
- Subject had a STEMI or NSTEMI within the last 3 months prior to enrollment.
- Subject is pregnant, breastfeeding, or planning to become pregnant in the next 365 days. Subjects (male and female) must agree to use effective birth control measures for duration of study.
- Subject is currently receiving oral or intravenous immunosuppressive therapy (e.g., inhaled steroids are not excluded).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04188262
|United States, Louisiana|
|Cardiovascular Institute of the South|
|Houma, Louisiana, United States, 70360|
|United States, Michigan|
|Mid-Michigan Heart & Vascular Center|
|Saginaw, Michigan, United States, 48604|
|United States, North Carolina|
|NC Heart & Vascular Research|
|Raleigh, North Carolina, United States, 27606|
|United States, Tennessee|
|Wellmont CVA Heart Institute|
|Kingsport, Tennessee, United States, 37660|
|Study Director:||Henry Hauser||Alucent Biomedical|
|Responsible Party:||Alucent Biomedical|
|Other Study ID Numbers:||
|First Posted:||December 5, 2019 Key Record Dates|
|Last Update Posted:||July 14, 2022|
|Last Verified:||July 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||Yes|
|Device Product Not Approved or Cleared by U.S. FDA:||Yes|
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases